Bank Of New York Mellon Corp Neurocrine Biosciences Inc Transaction History

Bank Of New York Mellon Corp

$538 Trillion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $180 Million - $214 Million	1,684,723 New	1,684,723 $201 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $3.45 Million - $4.05 Million	37,538 Added 2.2%	1,740,955 $185 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $24,555 - $32,422	324 Added 0.02%	1,703,417 $166 Million
Q1 2022 May 11, 2022	SELL	$72.45 - $94.81 $11.5 Million - $15.1 Million	-158,896 Reduced 8.53%	1,703,093 $160 Million
Q4 2021 Feb 11, 2022	SELL	$79.65 - $106.22 $3.19 Million - $4.25 Million	-40,058 Reduced 2.11%	1,861,989 $159 Million
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $9.79 Million - $11.2 Million	-113,584 Reduced 5.64%	1,902,047 $182 Million
Q2 2021 Aug 11, 2021	BUY	$89.43 - $102.27 $7.47 Million - $8.54 Million	83,484 Added 4.32%	2,015,631 $196 Million
Q1 2021 May 13, 2021	BUY	$87.57 - $119.4 $66.6 Million - $90.8 Million	760,465 Added 64.9%	1,932,147 $188 Million
Q4 2020 Feb 09, 2021	BUY	$86.91 - $108.33 $5.13 Million - $6.39 Million	58,975 Added 5.3%	1,171,682 $112 Million
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $13.5 Million - $18.9 Million	140,008 Added 14.39%	1,112,707 $107 Million
Q2 2020 Aug 12, 2020	BUY	$85.09 - $130.36 $12.7 Million - $19.5 Million	149,722 Added 18.19%	972,699 $119 Million
Q1 2020 May 06, 2020	BUY	$75.11 - $113.76 $14.6 Million - $22.1 Million	194,104 Added 30.87%	822,977 $71.2 Million
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $25.9 Million - $35.4 Million	-298,888 Reduced 32.22%	628,873 $67.6 Million
Q3 2019 Nov 07, 2019	SELL	$83.82 - $101.5 $2.11 Million - $2.56 Million	-25,181 Reduced 2.64%	927,761 $83.6 Million
Q2 2019 Aug 12, 2019	SELL	$72.24 - $91.27 $124,830 - $157,714	-1,728 Reduced 0.18%	952,942 $80.5 Million
Q1 2019 May 14, 2019	SELL	$69.31 - $91.53 $1.02 Million - $1.35 Million	-14,763 Reduced 1.52%	954,670 $84.1 Million
Q4 2018 Feb 11, 2019	SELL	$68.32 - $124.36 $2.76 Million - $5.03 Million	-40,421 Reduced 4.0%	969,433 $69.2 Million
Q3 2018 Nov 09, 2018	SELL	$98.88 - $125.85 $20.7 Million - $26.3 Million	-208,984 Reduced 17.15%	1,009,854 $0
Q2 2018 Aug 06, 2018	SELL	$75.3 - $105.99 $9.05 Million - $12.7 Million	-120,177 Reduced 8.98%	1,218,838 $120 Million
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $11.1 Million - $13.6 Million	-146,639 Reduced 9.87%	1,339,015 $111 Million
Q4 2017 Feb 09, 2018	BUY	$58.53 - $77.59 $87 Million - $115 Million	1,485,654	1,485,654 $115 Million

Others Institutions Holding NBIX

# of Institutions

625

Shares Held

94.2M

Call Options Held

632K

Put Options Held

621K

Black Rock Inc. New York, NY

14.2M
Shares

$1.78 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

10M
Shares

$1.26 Billion
0.02% of portfolio
State Street Corp Boston, MA

5.15M
Shares

$647 Million
0.02% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

2.57M
Shares

$323 Million
0.47% of portfolio
Bellevue Group Ag Kuesnacht, V8

1.86M
Shares

$234 Million
3.62% of portfolio

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account